Future Bumps In The Road For State-Funding Of Stem Cell Research

Stem cells, undifferentiated cells which have thepeople in March 2006 revealed a new problem. The
ability to turn into specific cell types, hold promise toholders of patents which already exist in the area
beneficially impact health problems such as diabetes,want future researchers (such as those in California)
Parkinson's and Alzheimer's diseases, stroke, heartto pay them for doing research utilizing their patents.
attack and spinal cord injury. Before his death,Ironically, the demand was made by one state
Christopher Reeve was a strong advocate of(Wisconsin's WARF) against another state (California's
research in stem cells.There has been controversyCIRM). With the announcement that South Korea will
about certain types of stem cells. There are threeproceed with patent applications of the disgraced
sources of stem cells, of which one type, cellsresearcher Woo Suk Hwang, one realizes that there
derived from early stage human embryos, hasare likely to be many patent holders in the field, all
caused political division, because the creation of anseeking to cash in on the large amounts of money
embryonic stem cell "line" requires the destruction ofbeing made available by states such as California,
a human embryo. Because of this, President Bush inNew Jersey, Maryland, Connecticut, and Illinois. An
2001, stated his intention to "allow federal funds toimportant message to appreciate is that money from
be used for research on existing stem cell lines,state-funding of stem cell research intended to
where the life and death decision has already beencreate new horizons in medical treatment may be
made," but no federal funds would be available fordirected to paying off holders of already-created
new stem cell lines. This choice has been debated.rights.Some of the problems may be resolved. A
The television show "60 Minutes" reviewed the issuerecent decision by the Supreme Court (Merck v.
twice in the month of February 2006, on February 12Integra) defines a large safe harbor for those
and on February 26.In the state of New Jersey, theconducting research needed to obtain federal
debate has been roughly on partisan lines, withregulatory approval (e.g., FDA approval). This research
Democrats favoring funding of stem reseach, andexemption may moderate the impact of claims such
(some) Republicans opposed. However, there is aas those by Wisconsin against California. However,
separate division as to "what kind" of stem cellexpectations of tangible results on a short time scale
research. Hedging its bets, New Jersey has proposedmay be unrealistic. One may question whether state
spending $150 million on cutting-edge research onfunding will produce any FDA approved embryonic
stem cells, including the controversial embryonic stemstem cell therapy in ten years. Patents issued in the
cells, $50 million on research on less controversialnext few years may be "too soon" in time because
research focused on stem cells from cord blood,commercialization of embryonic stem cell work is a
placentas and other human tissue, and $50 million onlong way off. This is an exciting time in a promising
a center directed to commercial applications andarea, but with the unknowns one must recognize
clinical trials of adult stem cells.The area of commercialthat there will be bumps in the road.Lawrence B.
applications has created unanticipated problems in theEbert is a registered patent attorney located in
brave new world of large-scale state-funding ofcentral New Jersey. He holds a Ph.D. from Stanford, a
research. A legal opinion in 2005 prepared forJ.D. from the University of Chicago, maintains a blog
California State Treasurer Angelides suggested thatat IPBiz.blogspot.com, and is the author of LESSONS
tax-exempt bonds could not be used to fundTO BE LEARNED FROM THE HWANG MATTER:
research wherein the state would share in moneyANALYZING INNOVATION THE RIGHT WAY,
generated by the research (specifically sharing inpublished in the Journal of the Patent & Trademark
payments by people who used patents generated byOffice Society [JPTOS] in March 2006.
the state-funded research). A meeting of stem cell